Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial

Response to SARS-CoV-2-vaccines in kidney-transplant recipients (KTR) is severely reduced. Heterologous3(rd) vaccination combining mRNA and vector vaccines did not increase seroconversion at 4 weeks after vaccination, but evolution of antibody levels beyond the first month remains unknown. We have r...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinzel, Andreas, Schrezenmeier, Eva, Regele, Florina, Hu, Karin, Raab, Lukas, Eder, Michael, Aigner, Christof, Jabbour, Rhea, Aschauer, Constantin, Stefanski, Ana-Luisa, Dörner, Thomas, Budde, Klemens, Reindl-Schwaighofer, Roman, Oberbauer, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353321/
https://www.ncbi.nlm.nih.gov/pubmed/35935786
http://dx.doi.org/10.3389/fmed.2022.936126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353321/
https://www.ncbi.nlm.nih.gov/pubmed/35935786
http://dx.doi.org/10.3389/fmed.2022.936126

Ejemplares similares